Endocarditis was confirmed by auscultation of a cardiac murmur and detection of valvular vegetations using trans-thoracic echocardiography (15)

Endocarditis was confirmed by auscultation of a cardiac murmur and detection of valvular vegetations using trans-thoracic echocardiography (15). Due to nonspecific clinical manifestation and laboratory parameters, brucellosis should be considered one of the differential diagnoses of any patient Abemaciclib Metabolites M2 suffering from obscure involvement of various organs in a brucellosis-endemic region. High percentage of relapses and therapeutic failures in spite of the use of currently recommended therapeutic regimens indicates the seriousness of this zoonosis and the need to control it. Brucellosis is a zoonosis caused by intracellular bacteria of the genusBrucella(1). The disease is widespread in many countries of the Mediterranean basin, and together with hydatidosis, trichinellosis, and leishmaniasis, it is considered to be a typical Mediterranean zoonosis (2). Human brucellosis is a multisystem disease whose patients present with nonspecific symptoms (3) and a high risk of complications, a protracted clinical course, and relapses (4). The main clinical characteristics of human brucellosis have been well known for a long time. Marston had been the first to give an accurate description of brucellosis as a disease entity even before the etiological agent was detected (5). The monographs published by Hughes in 1897 (6) and Spink in 1956 (7) contain perhaps the most detailed and still accurate data on this topic. Today, there is a lot of information about the characteristics of human brucellosis available from various parts of the world, and the description of its characteristics varies widely. For almost 30 years, brucellosis has been a dominant zoonosis in the Republic of Macedonia, causing a high morbidity and huge economic losses. However, the main reasons for persistence of the disease are not Abemaciclib Metabolites M2 only husbandry practices and traditional food and living Mouse monoclonal to CEA habits (2), but also an inadequate strategy of brucellosis control (8). The aim of our study was to present more detailed insights into the predominant demographic, epidemiological, clinical, and laboratory features of brucellosis patients, and their outcomes, during a 10-year period in the endemic region of the Republic of Macedonia. == Methods == This retrospective study included 550 patients who were diagnosed with brucellosis and treated at the University Clinic for Infectious Diseases and Febrile Conditions in Skopje between January 1998 and December 2007. The diagnosis was based on clinical findings compatible with brucellosis (arthralgia, fever, sweating, malaise, hepatomegaly, splenomegaly, signs of focal disease), supported by detection of specific antibodies at significant titers and/or demonstration of at least a 4-fold rise in antibody titer in serum samples obtained 3-4 weeks Abemaciclib Metabolites M2 apart. Antibody titers were determined by standard tube agglutination (STA),BrucellaCoombs test (9,10), or the Brucellacapt assay (11). The corresponding titers considered positive were 1/160, 1/320, and >1/320, respectively. During the study period, bacteriological isolation was not a routine practice in the Republic of Macedonia. Demographic and epidemiological data, clinical symptoms and signs, laboratory characteristics and outcome of the patients were analyzed. If a focal form of the disease was suspected after clinical examination, further investigations were performed, such as x-rays, electrocardiography, ultrasound investigations, lumbar puncture, radionuclide bone scan, computerized tomography, magnetic resonance imaging, and electromyography. The patients were treated with various combinations of two or three of the following drugs: (a) oral doxycycline at 100-200 mg/d in patients 8 years of age; (b) oral rifampin at 600-900 mg/d in adults or 15-20 mg/kg/d in children; (c) oral trimethoprim (TMP)-sulfamethoxazole (SMZ) combination therapy at TMP doses of 160-320 mg/d and SMZ doses of 800-1600 mg/d in adults, or TMP doses of 10-12 mg/kg/d and SMZ doses of 50-60 mg/kg/d in children; (d) oral ciprofloxacin at 1000 mg/d in adults; (e) intramuscular gentamicin at 240 mg/d in adults or 5 mg/kg/d in children, and (f) intravenous ceftriaxone at.